Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

541 results about "Alcohol dehydrogenase" patented technology

Alcohol dehydrogenases (ADH) (EC 1.1.1.1) are a group of dehydrogenase enzymes that occur in many organisms and facilitate the interconversion between alcohols and aldehydes or ketones with the reduction of nicotinamide adenine dinucleotide (NAD⁺) to NADH. In humans and many other animals, they serve to break down alcohols that otherwise are toxic, and they also participate in generation of useful aldehyde, ketone, or alcohol groups during biosynthesis of various metabolites. In yeast, plants, and many bacteria, some alcohol dehydrogenases catalyze the opposite reaction as part of fermentation to ensure a constant supply of NAD⁺.

Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme

The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
Owner:ABBVIE INC

Inhibitors of 11-beta hydroxysteroid dehydrogenase type I

Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein G, L, Q, Z, R6, R7, and R8 are defined herein.
Owner:BRISTOL MYERS SQUIBB CO

Use of compositions comprising an estrogenic component for the treatment and prevention of musculoskeletal pain

The present invention relates to a method of treating or preventing musculoskeletal pain in a mammal receiving administration of an estrogen. suppressant selected from the group consisting of aromatase inhibitors, GnRH analogues, cyclo-oxy-genase 2 (COX-2) inhibitors, 17β-hydroxysteroid dehydrogenase type 1 inhibitors, progestogens, anti-estrogens and combinations thereof, said method comprising the administration of an effective amount of an estrogenic component, wherein the estrogenic component is selected from the group consisting of: substances represented by the following formula (1) in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and / or precursors.
Owner:COELINGH BENNINK HERMAN JAN TIJMEN +1

Alcohol dehydrogenases (ADH) useful for fermentive production of lower alkyl alcohols

The invention relates to suitable candidate ADH enzymes for production of lower alkyl alcohols including isobutanol. The invention also relates to recombinant host cells that comprise such ADH enzymes and methods for producing lower alkyl alcohols in the same.
Owner:GEVO INC

Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors

Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein.
Owner:BRISTOL MYERS SQUIBB CO

17SS-HSD1 and STS inhibitors

The present invention relates to novel substituted steroid derivatives which represent selectiv inhibitors of the 17β-hydroxysteroid dehydrogenase type I (17β-HSD1) and, in addition, which may represent inhibitors of the steroid sulphatase, as well as to their salts, to pharmaceutical preparations containing these compounds and to processes for the preparation of these compounds. Furthermore, the invention concerns the therapeutic use of said novel substituted steroid derivatives, particularly their use in the treatment, inhibition, prophylaxis or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of 17β-hydroxysteroid dehydrogenase type I and / or steroid sulphatase enzymes and / or requiring the lowering of the endogenous 17β-estradiol concentration.
Owner:ABBVIE PHARMA GMBH

Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors

Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: W-L-Z   (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, L and Z are defined herein.
Owner:BRISTOL MYERS SQUIBB CO

Inhibitors of the 11-beta-hydroxysteroid dehydrogenaseType 1 enzyme and their therapeutic application

The present invention relates to the use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment or prophylactically treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions mediated by excessive glucocorticoid action.
Owner:ABBOTT LAB INC

Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme

The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
Owner:ABBVIE INC

Organisms for the production of cyclohexanone

ActiveUS20110014668A1BacteriaHydrolasesCyclohexanoneDiol Dehydratase
A non-naturally occurring microbial organism has cyclohexanone pathways that include at least one exogenous nucleic acid encoding a cyclohexanone pathway enzyme. A pathway includes a 2-ketocyclohexane-1-carboxyl-CoA hydrolase (acting on C—C bond), a 2-ketocyclohexane-1-carboxylate decarboxylase and an enzyme selected from a 2-ketocyclohexane-1-carboxyl-CoA hydrolase (acting on thioester), a 2-ketocyclohexane-1-carboxyl-CoA transferase, and a 2-ketocyclohexane-1-carboxyl-CoA synthetase. A pathway includes an enzyme selected from a 6-ketocyclohex-1-ene-1-carboxyl-CoA hydrolase (acting on C—C bond), a 6-ketocyclohex-1-ene-1-carboxyl-CoA synthetase, a 6-ketocyclohex-1-ene-1-carboxyl-CoA hydrolase (acting on thioester), a 6-ketocyclohex-1-ene-1-carboxyl-CoA transferase, a 6-ketocyclohex-1-ene-1-carboxyl-CoA reductase, a 6-ketocyclohex-1-ene-1-carboxylate decarboxylase, a 6-ketocyclohex-1-ene-1-carboxylate reductase, a 2-ketocyclohexane-1-carboxyl-CoA synthetase, a 2-ketocyclohexane-1-carboxyl-CoA transferase, a 2-ketocyclohexane-1-carboxyl-CoA hydrolase (acting on thioester), a 2-ketocyclohexane-1-carboxylate decarboxylase, and a cyclohexanone dehydrogenase. A pathway includes an adipate semialdehyde dehydratase, a cyclohexane-1,2-diol dehydrogenase, and a cyclohexane-1,2-diol dehydratase. A pathway includes a 3-oxopimelate decarboxylase, a 4-acetylbutyrate dehydratase, a 3-hydroxycyclohexanone dehydrogenase, a 2-cyclohexenone hydratase, a cyclohexanone dehydrogenase and an enzyme selected from a 3-oxopimeloyl-CoA synthetase, a 3-oxopimeloyl-CoA hydrolase (acting on thioester), and a 3-oxopimeloyl-coA transferase. Each these pathways can include a PEP carboxykinase. A method for producing cyclohexanone includes culturing these non-naturally occurring microbial organisms.
Owner:GENOMATICA INC

Method for producing an l-amino acid using a bacterium of the enterobacteriaceae family

A method for producing an L-amino acid is described, for example L-threonine, L-lysine, L-histidine, L-phenylalanine, L-arginine, L-tryptophan, or L-glutamic acid, using a bacterium of the Enterobacteriaceae family, wherein the bacterium has been modified to enhance an activity of a wild-type alcohol dehydrogenase encoded by the adhE gene or a mutant alcohol dehydrogenase which is resistant to aerobic inactivation.
Owner:AJINOMOTO CO INC

Method for biosynthesis of tyrosol in Escherichia coli and application of tyrosol

ActiveCN104099379ABacteriaMicroorganism based processesEscherichia coliPhenylacetaldehyde dehydrogenase
The invention relates to a method for biosynthesis of tyrosol in Escherichia coli and application of tyrosol, which belongs to the field of bioengineering technology. According to the method for biosynthesis of tyrosol in Escherichia coli, tyrosine or glucose is used as a substrate, (4-hydroxyphenyl)pyruvic acid is produced under the catalysis of ammonialyase coded by Escherichia coli; (4-hydroxyphenyl)acetaldehyde is produced under the action of the microzyme 4-hydroxyphenylpyruvate decarboxylase; (4-hydroxyphenyl)acetaldehyde is catalyzed by alcohol dehydrogenase so as to produce tyrosol; and a phenylacetaldehyde dehydrogenase gene of Escherichia coli is knocked out at the same time so as to block the transformation channel for (4-hydroxyphenyl)acetaldehyde into (4-hydroxyphenyl)acetic acid and promote accumulation of (4-hydroxyphenyl)acetaldehyde and transformation of (4-hydroxyphenyl)acetaldehyde into tyrosol. The invention provides a novel production approach for tyrosol; and the method lays a foundation for large-scale industrial production of tyrosol and has important economic values and social benefits.
Owner:TIANJIN INST OF IND BIOTECH CHINESE ACADEMY OF SCI

Method for producing tyrosol and hydroxytyrosol through heterologous metabolic pathways

The invention discloses a method for producing tyrosol and hydroxytyrosol through heterologous metabolic pathways, wherein metabolic pathways for producing hydroxytyrosol are introduced into hosts forproducing the hydroxytyrosol; more specifically, the method comprises the following steps: producing tyrosol by efficiently expressing aminotransferase, ketoacid decarboxylase and alcohol dehydrogenase in the hosts, then introducing 4-hydroxyphenylacetate hydroxylase to produce the hydroxytyrosol. Genes coded by the enzymes are constructed on an expression plasmid or integrated to a genome. Through the method, production hosts capable of producing the hydroxytyrosol by using glucose, glycerinum and tyrosine can be prepared by introducing the genes coded by the enzymes to the hosts; meanwhile,the invention also discloses a biphasic cultivation method, so that the production of the hydroxytyrosol is more efficient.
Owner:BEIJING UNIV OF CHEM TECH

Production of omega-amino fatty acids

ActiveUS20140178948A1FungiBacteriaAlkane HydroxylaseIodo fatty acid
The invention provides a whole cell catalyst which expresses a recombinant α-dioxygenase or the combination of a recombinant fatty acid reductase and a phosphopantetheinyl transferase phosphopantetheinylating the fatty acid reductase, and which in addition to the α-dioxygenase and / or the combination of fatty acid reductase and phosphopantetheinyl transferase expresses a transaminase, characterized in that the phosphopantetheinyl transferase and / or transaminase is preferably recombinant; and a method for the conversion of a fatty acid, ω-hydroxy fatty acid, ω-oxo fatty acid or a monoester thereof to an amine, comprising oxidation of the fatty acid, ω-hydroxy fatty acid, ω-oxo fatty acid or the monoester thereof to an oxidation product by contacting with an alkane hydroxylase and / or alcohol dehydrogenase, contacting the oxidation product with a phosphopantetheinylated fatty acid reductase or a α-dioxygenase to give an aldehyde, and contacting the aldehyde with a transaminase.
Owner:EVONIK OPERATIONS GMBH

7beta-hydroxyl sterol dehydrogenase mutant and application thereof to preparation of ursodeoxycholic acid

The invention discloses a 7beta-hydroxyl sterol dehydrogenase mutant which is obtained by protein engineering and of which coenzyme preference is changed, a coding gene of the 7beta-hydroxyl sterol dehydrogenase mutant, a recombinant expression vector and a recombinant expression transformant which contain a sequence of the gene, a preparation method of a recombinant mutant enzyme preparation, andapplication of the recombinant mutant enzyme preparation to preparation of ursodeoxycholic acid. By co-enzyme regeneration of enzymic coupling, the recombinant mutant enzyme preparation disclosed bythe invention can efficiently utilize relatively cheap oxidized coenzyme I (NAD+) instead of very expensive oxidized coenzyme II (NADP+); asymmetric reduction of catalytic 7-hydroxyl lithocholic acideffectively reduces production cost; moreover, the recombinant mutant enzyme preparation has the advantages of simplicity for operation, mild reaction condition, environmental-friendliness, high yieldand the like, and has a good application prospect in preparation of ursodeoxycholic acid by epimerization of chenodesoxycholic acid.
Owner:EAST CHINA UNIV OF SCI & TECH +1

Modified alcohol dehydrogenases for the production of fuels and chemicals

The present invention relates to recombinant microorganisms comprising biosynthetic pathways and methods of using said recombinant microorganisms to produce various beneficial metabolites. In various aspects of the invention, the recombinant microorganisms may further comprise one or more modifications resulting in the reduction or elimination of 3 keto-acid (e.g., acetolactate and 2-aceto-2-hydroxybutyrate) and / or aldehyde-derived by-products. In various embodiments described herein, the recombinant microorganisms may be microorganisms of the Saccharomyces clade, Crabtree-negative yeast microorganisms, Crabtree-positive yeast microorganisms, post-WGD (whole genome duplication) yeast microorganisms, pre-WGD (whole genome duplication) yeast microorganisms, and non-fermenting yeast microorganisms.
Owner:CALIFORNIA INST OF TECH +1

XZ-A26 bacterial strain for producing L-alanine with high yield as well as construction method and application of XZ-A26 bacterial strain

The invention discloses an XZ-A26 bacterial strain for producing L-alanine with high yield, which has a preservation number of CGMCC (China General Microbiological Culture Collection Center) No.4036 and has the capacity of generating high-concentration L-alanine through fermentation. The XZ-A26 bacterial strain is constructed by the steps of: integrating an L-alanine dehydrogenase gene on thermophilic fatty bacillus chromosome on lactic dehydrogenase position on an escherichia coli ATCC8739 chromosome, then sequentially knocking out a pyruvate formate lyase gene, an alcohol dehydrogenase gene, an acetokinase gene, a fumaric acid reductase gene and an alanine racemase gene of the escherichia coli chromosome, and then carrying out continuous cell culture in a fermenting tank for obtaining agenetic engineering strain. The invention also relates to a construction method of the XZ-A26 bacterial strain and an application of the XZ-A26 bacterial strain in preparation of the L-alanine. According to the invention, the escherichia coli with the preservation number of CGMCC No.4036 for generating the high-concentration L-alanine through fermentation can be constructed by using a metabolic engineering method, and the yield of the L-alanine generated by using the XZ-A26 bacterial strain reaches up to 115g / L. The XZ-A26 bacterial strain is suitable for industrially producing the L-alanine.
Owner:ANHUI HUAHENG BIOTECH

Genetic modification for production of 3-hydroxypropionic acid

InactiveUS20120329110A1Improve production yield and producibilityIncrease productivityFungiBacteriaLactate dehydrogenaseMetabolite
A method of increasing 3-HP production efficiency by inhibiting expression of a lactate dehydrogenase, a phosphotransacetylase, and an alcohol dehydrogenase in production of 3-HP using a malonic semialdehyde reduction pathway to prevent metabolite leak and increase a malonyl-CoA pool is disclosed.
Owner:SAMSUNG ELECTRONICS CO LTD

Application of alcohol dehydrogenase in catalytic generation of ethyl (R)-4-chloro-3-hydroxy butyrate

The invention discloses application of alcohol dehydrogenase with amino acid sequence disclosed as SEQ ID NO:2 in preparing ethyl (R)-4-chloro-3-hydroxy butyrate from ethyl 4-chloroacetoacetate by asymmetric reduction. By using alcohol dehydrogenase with amino acid sequence disclosed as SEQ ID NO:2 as a catalyst, ethyl 4-chloroacetoacetate as a substrate and NADH (nicotinamide adenine dinucleotide) as a cofactor, asymmetric reduction is carried out to prepare the ethyl (R)-4-chloro-3-hydroxy butyrate. The invention applies the alcohol dehydrogenase with amino acid sequence disclosed as SEQ ID NO:2 in preparing ethyl (R)-4-chloro-3-hydroxy butyrate from ethyl 4-chloroacetoacetate by asymmetric reduction for the first time, and has favorable effect. The enzyme activity is up to 5.6 U / mg, the yield of the substrate is up to 94%, and the enantiomeric excess value of the product is 100%. The yield is high, and the production cost is greatly lowered.
Owner:NANJING UNIV OF TECH

Novel 17beta-hydroxysteroid dehydrogenase type I inhibitors

3,15-substituted estrone compounds which act as inhibitors of 17β-hydroxysteroid dehydrogenase type I (17β-HSD1), salts thereof, pharmaceutical preparations containing such compounds, processes for preparing such compounds, and therapeutic uses of such compounds, particularly in the treatment or inhibition of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of 17β-hydroxysteroid dehydrogenase type I enzymes and / or requiring the lowering of the endogenous 17β-estradiol concentration, as well as the general use of selective 17β-hydroxysteroid dehydrogenase type 1 inhibitors which possess in addition no or only pure antagonistic binding affinities to the estrogen receptor for the treatment or inhibition of benign gynecological disorders, particularly endometriosis.
Owner:ABBVIE PHARMA GMBH

Alcohol dehydrogenase, gene and recombinase thereof, and application of alcohol dehydrogenase in synthesis of chiral diaryl secondary alcohol

The invention discloses an alcohol dehydrogenase, a gene thereof, a recombinant expression vector and a recombinant expression transformant respectively containing the gene, a recombinase of the alcohol dehydrogenase, and an application of the alcohol dehydrogenase in asymmetric reduction synthesis of chiral diaryl secondary alcohol as a catalyst, and belongs to the technical field of bioengineering. The alcohol dehydrogenase is from Kluyveromyces sp. CCTCCM2011385, has a carbonyl group reduction function, and also has a hydroxy group oxidation function. Extra addition of glucose dehydrogenase and other enzymes used for cofactor circulation is not needed when the alcohol dehydrogenase is used in the reduction of diaryl ketone into the chiral diaryl secondary alcohol as a biocatalyst, and the alcohol dehydrogenase has the advantages of high catalysis efficiency, mild reaction conditions, easy product recovery and low cost, so the alcohol dehydrogenase has very good application and exploitation prospect in the production of antihistamine medicines.
Owner:JIANGNAN UNIV

Preparation method of corn sobering-up peptide

The invention discloses a corn sobering-up peptide and a preparation method thereof. In the method, corn gluten meal is taken as a raw material for the product provided by the invention, alkali protease Alcalase is adopted for hydrolysis for 2 hours under optimal conditions, compound protease Protamex is further added for hydrolysis for 3 hours under the optimal conditions, and corn sobering-up peptide powder is obtained by crude separation, ultrafiltration, concentration and spray forming. The peptide section with the molecular weight of less than 1200Da in the product accounts for 73.19%, and the content of lactamic acid and the content of aminocarproic acid are greater than 6.43% and 12.42% respectively. The product can generate stable nicotinamide adenine adinucleotide (NAD<+>) by improving the concentration of the lactamic acid and aminocarproic acid in blood, enhance the activity of alcohol dehydrogenase and acetaldehyde dehydrogenase, promote decomposition and metabolism of ethanol in vivo, thereby reducing the concentration of the ethanol in the blood, increasing the supply of coenzyme, playing a role in protecting liver and playing a role in preventing liver damages caused by alcohol, such as fatty liver and the like.
Owner:QIQIHAR UNIVERSITY

Glucose Dehydrogenase/Cytochrome Fusion Protein

A fusion protein of pyrroloquinoline quinone glucose dehydrogenase (PQQGDH) and a cytochrome is disclosed. PQQGDH is, for example, a water-soluble PQQGDH derived from Acinetobacter calcoaceticus. The cytochrome is, for example, an electron transfer domain of quinohemoprotein ethanol dehydrogenase from Comamonas testosteroni. The fusion protein of the present invention shows intramolecular electron transfer from PQQ, a redox center, to the cytochrome, which allow construction of a direct electron transfer-type glucose sensor which requires no electron mediators.
Owner:ARKRAY INC

Alcohol dehydrogenase mutant, gene thereof, and application thereof in preparation of chiral diaryl alcohol

The invention discloses an alcohol dehydrogenase mutant, an encoding gene thereof, and an application thereof in the preparation of chiral diaryl alcohol. The mutant is obtained through substituting serine in the 237th position of alcohol dehydrogenase from Kluyveromyces sp.CCTCC M2011385 and with the amino acid sequence represented by SEQ ID No.1 with alanine. The alcohol dehydrogenase mutant has greatly higher reduction activity and stereoselectivity than wild enzymes. The mutant is especially suitable for asymmetric reduction of diaryl ketone to prepare chiral diaryl alcohol, and can be used to synthesize various antihistamine medicines. The alcohol dehydrogenase mutant has good industrial application prospect.
Owner:JIANGNAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products